Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Julphar
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Cipla
Argus Health
Deloitte
Chinese Patent Office

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,419,958

« Back to Dashboard

Summary for Patent: 6,419,958
Title: Extended release formulation of venlafaxine hydrochloride
Abstract:This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
Inventor(s): Sherman; Deborah M. (Plattsburgh, NY), Clark; John C. (Peru, NY), Lamer; John U. (St. Albans, VT), White; Steven A. (Champlain, NY)
Assignee: Wyeth (Madison, NJ)
Application Number:09/884,412
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 6,419,958

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,419,958

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 77145 ➤ Try a Free Trial
Taiwan 555568 ➤ Try a Free Trial
Taiwan 493993 ➤ Try a Free Trial
Turkey 200001232 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Federal Trade Commission
Fish and Richardson
Argus Health
Daiichi Sankyo
Teva
AstraZeneca
Johnson and Johnson
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.